Evidence suggests that aberrant CCNB1 expression is correlated with unfavorable survival outcomes in various cancers, including ovarian carcinoma, prostate cancer, and lung adenocarcinoma [53–56]. Here, CCNB1 is linked to prostate carcinoma.